PrismaSol is for continuous renal replacement therapy (CRRT) is a common modality for management of acute renal failure in critical ill patients. This therapy provides slow removal of fluids and solutes intended to substitute for impaired renal function over an extended period of time.

This purchase is exempt from the usual selection processes of the Procurement Code because the procurement expenditure is for medical supplies or medical services necessary for the delivery of care and treatment at medical, dental, or veterinary teaching facilities utilized by SIU or U of I (30 ILCS 500 / 1-13(b-5)) Baxter's PrismaSol is the only FDA approved custom solution in the marketplace. It is essential therapy for selected patients; without it, could lead to negative clinical outcome of the patient.